Skip to main content Accessibility help
×
Hostname: page-component-84b7d79bbc-dwq4g Total loading time: 0 Render date: 2024-07-28T10:06:59.906Z Has data issue: false hasContentIssue false

27 - Clobazam

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Onfi, Frisium (EU)

Generic?

• No

Class

• Benzodiazepine, antiepileptic drug (AED)

Commonly Prescribed for

(FDA approved in bold)

Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older

• Adjunctive therapy for refractory focal seizure, general tonic-clonic seizure, Dravet syndrome, benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, catamenial seizure, cluster seizure

• Acute or chronic anxiety

How the Drug Works

• Potentiation of GABAergic neurotransmission resulting from binding to the GABAA receptor

How Long Until It Works

• Tmax = 0.5–4 hours. May take days to weeks

If It Works

• May consider tapering after seizure free for 2 years, depending on the seizure type

If It Doesn't Work

• Consider changing to another agent, adding a second agent, using a medical device, or a referral for epilepsy surgery evaluation. When adding a second agent, keep drug interactions in mind

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Consider a tertiary care or switch to other agents

Tests

• Not required

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• CNS inhibitory effect from actions on benzodiazepine receptors

Notable AEs

• Constipation, somnolence, pyrexia, lethargy, drooling, and withdrawal symptoms

Life-Threatening or Dangerous AEs

• Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)

Weight Gain

• Not unusual

Sedation

• Not unusual

What to Do About AEs

• If SJS or TEN, hospitalization is required

• Discontinue or switch to another agent

Best Augmenting Agents to Reduce AEs

• Most AEs cannot be reduced by an augmenting agent

DOSING AND USE

• 20–40 mg/day twice daily

Dosage Forms

• Tablet: 10 and 20 mg

• Oral suspension: 2.5 mg/mL in 120 mL bottles

How to Dose

• ≤ 30 kg: starting dose 5 mg; starting 7th day 10 mg; starting 14th day 20 mg

• 30 kg: starting dose 10 mg; starting 7th day 20 mg; starting 14th day 40 mg

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 99 - 101
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Clobazam
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.028
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Clobazam
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.028
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Clobazam
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.028
Available formats
×